Mohamed Abdulbagi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mohamed Abdulbagi has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Bin Di
China Pharmaceutical University
3 shared publications - Bo Li
Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 210009, China
3 shared publications - Shaza Wagiealla Shantier
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Khartoum, Khartoum, Sudan
2 shared publications A. A. I. Ibrahim
National Medicines and Poisons Board/National Drugs Quality Control and Research Laboratory, Khartoum, Sudan
1 shared publicationA. E. Khalid
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Khartoum, Khartoum, Sudan
1 shared publicationA. H. Fadul
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Khartoum, Khartoum, Sudan
1 shared publication
Latest Publications
- 1 July 2025
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 265, 117047
Investigating peroxide-induced Asp46 epimerization in peroxiredoxin 2 using enzymatic hydrolysis and LC-MS/MS
- 1 July 2025
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 265, 117047
Investigating peroxide-induced Asp46 epimerization in peroxiredoxin 2 using enzymatic hydrolysis and LC-MS/MS
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Spectroscopy
- Vol. 2025 (1)
A Rapid and Cost‐Effective Absorption Factor Method for the Multicomponent Quantification of Paracetamol and Orphenadrine
In this work, we aimed to develop and validate a new absorption factor spectrophotometric method for the assay of the paracetamol (PRA) and orphenadrine (ORP) combination in bulk and tablet dosage form. The method utilizes mathematical processing of the total absorbance of the PRA‐ORP mixture at two precisely selected wavelengths (203 and 243 nm). Employing the established absorption factor of standard PRA at these wavelengths, the individual absorbance of each drug within the mixture is obtained, eliminating the need for prior separation. The method showed excellent linearity for both drugs within the concentration range of 2–14 μg/mL, and the correlation coefficients ( R 2 ) were 0.9985 and 0.9986 for PRA and ORP, respectively. The limit of detection (LOD) values were determined to be 0.14 μg/mL for PRA and 0.16 μg/mL for ORP. Similarly, the limit of quantification (LOQ) values were 0.44 and 0.48 μg/mL for PRA and ORP, respectively. Furthermore, the method exhibited high accuracy, with recoveries ranging from 99% to 102%, and excellent precision, demonstrated by relative standard deviation (%RSD) values below 2%. These findings confirm the validity of our developed method for the routine analysis of PRA and ORP in both bulk and tablet dosage forms, making it a practical and cost‐effective approach for quality control purposes.
- 1 January 2025
- Published by Wiley in Journal of Spectroscopy
- Vol. 2025 (1)
Open AccessA Rapid and Cost‐Effective Absorption Factor Method for the Multicomponent Quantification of Paracetamol and Orphenadrine
In this work, we aimed to develop and validate a new absorption factor spectrophotometric method for the assay of the paracetamol (PRA) and orphenadrine (ORP) combination in bulk and tablet dosage form. The method utilizes mathematical processing of the total absorbance of the PRA‐ORP mixture at two precisely selected wavelengths (203 and 243 nm). Employing the established absorption factor of standard PRA at these wavelengths, the individual absorbance of each drug within the mixture is obtained, eliminating the need for prior separation. The method showed excellent linearity for both drugs within the concentration range of 2–14 μg/mL, and the correlation coefficients ( R 2 ) were 0.9985 and 0.9986 for PRA and ORP, respectively. The limit of detection (LOD) values were determined to be 0.14 μg/mL for PRA and 0.16 μg/mL for ORP. Similarly, the limit of quantification (LOQ) values were 0.44 and 0.48 μg/mL for PRA and ORP, respectively. Furthermore, the method exhibited high accuracy, with recoveries ranging from 99% to 102%, and excellent precision, demonstrated by relative standard deviation (%RSD) values below 2%. These findings confirm the validity of our developed method for the routine analysis of PRA and ORP in both bulk and tablet dosage forms, making it a practical and cost‐effective approach for quality control purposes.
- 20 November 2024
- Published by Springer Nature in Journal of Applied Spectroscopy
- Vol. 91 (5) , 1-8
Development and Validation of Direct UV-Spectrophotometric Methods for the Analysis of Folic Acid in Bulk and Dosage Form
- 20 November 2024
- Published by Springer Nature in Journal of Applied Spectroscopy
- Vol. 91 (5) , 1-8
Development and Validation of Direct UV-Spectrophotometric Methods for the Analysis of Folic Acid in Bulk and Dosage Form
- 17 November 2023
- Published by Taylor & Francis in Critical Reviews in Analytical Chemistry
- Vol. 55 (2) , 306-315
Resolving D-Amino Acid Containing Peptides Using Ion Mobility-Mass Spectrometry: Challenges and Recent Developments
Peptides and proteins having D-amino acids in their sequences are now believed to be widespread among different living organisms. Their significance is attributed to the diverse functions of these molecules, such as having a certain pathological implication or enhancing biological activity. Indeed, some peptide molecules with D-amino acids in their structure have already found their way to clinical use such as the antibacterial gramicidin and the antidiabetic nateglinide. Ion mobility mass spectrometry (IM-MS) added an additional dimension of separation as it depends on ions mobility in the space, which is dependent on their shapes, and the shape depends on the orientation of atoms. Thus, D-amino acids containing peptides (DAACPs) will have different mobility and collision cross-section values than those with L-amino acids. Eventually, this will lead to baseline separation of the two peptides. Additionally, ion mobility can precisely locate the position of D-amino acids by analyzing the difference in the arrival times of the fragment ions. The importance of DAACPs, as well as the difficulties in discovering them, were addressed in this review. Similarly, we emphasized how recent developments in IM-MS have improved their detection and analysis. Consequently, the LC-IM-MS/MS platform appears to be promising in isomeric mixture analysis.
- 17 November 2023
- Published by Taylor & Francis in Critical Reviews in Analytical Chemistry
- Vol. 55 (2) , 306-315
Resolving D-Amino Acid Containing Peptides Using Ion Mobility-Mass Spectrometry: Challenges and Recent Developments
Peptides and proteins having D-amino acids in their sequences are now believed to be widespread among different living organisms. Their significance is attributed to the diverse functions of these molecules, such as having a certain pathological implication or enhancing biological activity. Indeed, some peptide molecules with D-amino acids in their structure have already found their way to clinical use such as the antibacterial gramicidin and the antidiabetic nateglinide. Ion mobility mass spectrometry (IM-MS) added an additional dimension of separation as it depends on ions mobility in the space, which is dependent on their shapes, and the shape depends on the orientation of atoms. Thus, D-amino acids containing peptides (DAACPs) will have different mobility and collision cross-section values than those with L-amino acids. Eventually, this will lead to baseline separation of the two peptides. Additionally, ion mobility can precisely locate the position of D-amino acids by analyzing the difference in the arrival times of the fragment ions. The importance of DAACPs, as well as the difficulties in discovering them, were addressed in this review. Similarly, we emphasized how recent developments in IM-MS have improved their detection and analysis. Consequently, the LC-IM-MS/MS platform appears to be promising in isomeric mixture analysis.
- 31 October 2023
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 238, 115834
Separation and characterization of related substances of Lurasidone hydrochloride by LC-QTOF-MS techniques
- 31 October 2023
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 238, 115834
Separation and characterization of related substances of Lurasidone hydrochloride by LC-QTOF-MS techniques
- Open Access
- 18 November 2021
- Published by MDPI AG in Biomolecules
- Vol. 11 (11) , 1716
D-Amino Acids and D-Amino Acid-Containing Peptides: Potential Disease Biomarkers and Therapeutic Targets?
In nature, amino acids are found in two forms, L and D enantiomers, except for glycine which does not have a chiral center. The change of one form to the other will lead to a change in the primary structure of proteins and hence may affect the function and biological activity of proteins. Indeed, several D-amino acid-containing peptides (DAACPs) were isolated from patients with cataracts, Alzheimer’s and other diseases. Additionally, significant levels of free D-amino acids were found in several diseases, reflecting the disease conditions. Studying the molecular mechanisms of the DAACPs formation and the alteration in D-amino acids metabolism will certainly assist in understanding these diseases and finding new biomarkers and drug targets. In this review, the presence of DAACPs and free D-amino acids and their links with disease development and progress are summarized. Similarly, we highlight some recent advances in analytical techniques that led to improvement in the discovery and analysis of DAACPs and D-amino acids.
- 18 November 2021
- Published by MDPI AG in Biomolecules
- Vol. 11 (11) , 1716
Open AccessD-Amino Acids and D-Amino Acid-Containing Peptides: Potential Disease Biomarkers and Therapeutic Targets?
In nature, amino acids are found in two forms, L and D enantiomers, except for glycine which does not have a chiral center. The change of one form to the other will lead to a change in the primary structure of proteins and hence may affect the function and biological activity of proteins. Indeed, several D-amino acid-containing peptides (DAACPs) were isolated from patients with cataracts, Alzheimer’s and other diseases. Additionally, significant levels of free D-amino acids were found in several diseases, reflecting the disease conditions. Studying the molecular mechanisms of the DAACPs formation and the alteration in D-amino acids metabolism will certainly assist in understanding these diseases and finding new biomarkers and drug targets. In this review, the presence of DAACPs and free D-amino acids and their links with disease development and progress are summarized. Similarly, we highlight some recent advances in analytical techniques that led to improvement in the discovery and analysis of DAACPs and D-amino acids.